Keros Therapeutics, Inc. (KROS) is experiencing a decline in its stock price today, which may be attributed to recent changes in institutional ownership. Quest Partners LLC significantly reduced its stake in the company by 86.9% during the third quarter, as reported in a recent filing with the Securities & Exchange Commission. This reduction involved selling 4,177 shares, leaving Quest Partners with only 632 shares valued at $37,000. Such a substantial decrease in holdings by an institutional investor can often lead to negative sentiment among other investors, potentially contributing to the downward pressure on the stock.
The current price of Keros Therapeutics is $56.29, reflecting a 2.51% decrease from its previous close of $57.74. The stock opened at $57.35 and has seen a 1.85% decline from the opening price.